oxybutynin (Tavor)

358  relevant articles (64 outcomes, 81 trials/studies) found for this Drug

Tavor; Ryol; Ditropan; Oxytrol; 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate; 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate; AbZ brand of oxybutynin hydrochloride; Abbott brand of oxybutynin hydrochloride; Aliud brand of oxybutynin hydrochloride; Allphar brand of oxybutynin hydrochloride; Alpharma brand of oxybutynin hydrochloride; Apo-Oxybutynin; Apotex brand of oxybutynin hydrochloride; Asofarma brand of oxybutynin hydrochloride; Aventis brand of oxybutynin hydrochloride; Azupharma brand of oxybutynin hydrochloride; Berk brand of oxybutynin hydrochloride; Byk brand of oxybutynin hydrochloride; CCD brand of oxybutynin hydrochloride; Clonmel brand of oxybutynin hydrochloride; Contimin; Cystonorm; Cystrin; Dresplan; Dridase; Driptane; Fournier brand of oxybutynin hydrochloride; Gen-Oxybutynin; Genpharm brand of oxybutynin hydrochloride; Heumann brand of oxybutynin hydrochloride; Hoyer brand of oxybutynin hydrochloride; Janssen brand of oxybutynin hydrochloride; Kade brand of oxybutynin hydrochloride; Novo-Oxybutynin; Novopharm brand of oxybutynin hydrochloride; Nu-Oxybutyn; Nu-Pharm brand of oxybutynin hydrochloride; Ortho brand of oxybutynin hydrochloride; Oxyb AbZ; Oxybugamma; Oxybutin Holsten; Oxybuton; Oxybutynin AL; Oxybutynin AZU; Oxybutynin Heumann; Oxybutynin Hexal; Oxybutynin Stada; Oxybutynin-Puren; Oxybutynin-ratiopharm; Oxymedin; PMS-Oxybutynin; Pfleger brand of oxybutynin hydrochloride; Pharmascience brand of oxybutynin hydrochloride; Pollakisu; Renamel; Sanofi Synthelabo brand of oxybutynin hydrochloride; Seid brand of oxybutynin hydrochloride; Spasmex Oxybutynin; Spasyt; Stadapharm brand of oxybutynin hydrochloride; TAD brand of oxybutynin hydrochloride; Wörwag brand of oxybutynin hydrochloride; Zatur; ct-Arzneimittel brand of oxybutynin hydrochloride; esparma brand of oxybutynin hydrochloride; oxybutynin chloride; oxybutynin hydrochloride; oxybutynin von ct; ratiopharm brand of oxybutynin hydrochloride

Relationship Network

Drug Context: Research Results

Experts

1.	Dmochowski, Roger R: 9 articles (01/2007 - 08/2002)
2.	Sand, Peter K: 6 articles (01/2007 - 06/2003)
3.	Davila, G Willy: 6 articles (11/2006 - 08/2002)
4.	Oki, Tomomi: 3 articles (02/2007 - 11/2004)
5.	Yamada, Shizuo: 3 articles (02/2007 - 11/2004)
6.	Armstrong, Robert B: 3 articles (01/2007 - 01/2005)
7.	Jumadilova, Zhanna: 3 articles (12/2006 - 07/2005)
8.	Albrecht, Detlef: 3 articles (01/2005 - 01/2002)
9.	Staskin, D R: 2 articles (01/2008 - 04/2001)
10.	Sand, Peter: 2 articles (04/2007 - 01/2002)

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 01/01/2002 - "While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth" 03/01/1995 - "In summary, oxybutynin is one of the few drugs proven to be beneficial in some patients with overactive detrusor function" 12/01/2003 - "Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride" 10/20/2005 - "Of these derivatives, (+)-(1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydrochloride (9b) exhibited almost the same inhibitory activity against bladder contraction to that of oxybutynin (1), and more than 10-fold selectivity for bladder contraction versus salivary secretion, demonstrating that 9b may be useful for the treatment of symptoms associated with overactive bladder without having side effects such as dry mouth." 01/01/2000 - "Intravesical oxybutynin chloride has been reported to be effective for overactive bladder, although sometimes the efficacy does not last long enough" Get all the results and reference details, order at left...
2.	Urge Urinary Incontinence (Urge Incontinence) 01/01/2005 - "Although most novel anticholinergic medications are effective and well tolerated in children, in our experience oxybutynin extended release provides superior relief for urge urinary incontinence in children" 07/01/2001 - "CONCLUSIONS: Transdermal delivery of oxybutynin resulted in comparable efficacy and a significantly improved anticholinergic side effect profile compared with oral administration in adults with urge urinary incontinence." 06/01/1990 - "We found oxybutynin chloride significantly more effective than placebo at reducing the symptoms of urgency and urge incontinence and more effective at reducing the height of the highest unstable detrusor contraction" 12/01/2003 - "Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral therapy and to endure incontinence" 10/01/2005 - "MATERIALS AND METHODS: Data were combined from 3 flexible dosing studies of a total of 420 patients with urge urinary incontinence or mixed incontinence in whom ER oxybutynin dose adjustments were made to achieve the optimal balance between efficacy and tolerability, as judged by each participant" Get all the results and reference details, order at left...
3.	Neurogenic Urinary Bladder (Bladder, Neurogenic) 11/01/2006 - "Oxybutynin is extremely safe and effective in almost every population including children, the elderly, and those who have neurogenic bladder" 05/01/2001 - "CONCLUSIONS: Oral and intravesical oxybutynin is effective for managing neurogenic bladder dysfunction, but intravesical administration is safer and better tolerated than oral oxybutynin in the treatment of children with MMC" 11/01/1993 - "Oral administration of oxybutynin chloride is effective in increasing bladder capacity in patients with neurogenic bladder dysfunction who are practising clean intermittent catheterisation, but it is often associated with systemic side effects" 01/01/2004 - "A few noncomparative studies have shown promising results with oxybutynin ER in the treatment of adult and paediatric patients with neurogenic bladder dysfunction secondary to neuronal injury" 03/01/1988 - "The present long-term trial proved that oxybutynin hydrochloride is an exceedingly effective and safe agent for clinical management of unstable bladder and overactive neurogenic bladder." Get all the results and reference details, order at left...
4.	Urinary Incontinence 10/01/2005 - "CONCLUSIONS: Individualized dosing with ER oxybutynin was associated with highly effective and well tolerated control of urinary incontinence with more than 40% of patients achieving total dryness." 01/01/2007 - "Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials." 03/01/2006 - "PATIENTS AND METHODS: Patients who reported urinary incontinence (UI) (one or more episodes/diary) and voiding frequency (eight or more voids/day) or urgency (one or more episodes/diary) during a 2-week baseline were randomized to once-daily 5, 10 or 15 mg CR oxybutynin for 4 weeks" 01/01/2004 - "Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence." 10/01/2003 - "Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence." Get all the results and reference details, order at left...
5.	Nocturnal Enuresis (Bedwetting) 09/01/1992 - "In children, the drug is prescribed most frequently (56%) for conditions outside the licensed indications, particularly nocturnal enuresis, a condition for which the efficacy of Ditropan has not been established" 11/01/2007 - "PURPOSE: We assessed prospectively the efficacy of holding exercises and/or antimuscarinics (oxybutynin chloride and placebo) for increasing maximum voided volume in prepubertal children with monosymptomatic nocturnal enuresis" 11/01/2007 - "CONCLUSIONS: In the treatment of children with monosymptomatic nocturnal enuresis maximum voided volume can be increased significantly through holding exercises, but not with oxybutynin chloride alone" 12/01/2002 - "OBJECTIVES: To evaluate children with refractory monosymptomatic nocturnal enuresis to determine whether detrusor overactivity (DOA) plays a role in 4 weeks of unsuccessful treatment with retention control training (RCT); whether an increase in bladder capacity can eventually be obtained by RCT plus oxybutynin; and whether the increase in capacity is the primary key to success" 01/01/1993 - "Sixty-three children with persistent nocturnal enuresis were urodynamically assessed and subsequently treated with oxybutynin chloride" Get all the results and reference details, order at left...
95 Diseases and 358 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	tolterodine (Detrol)
2.	oxybutynin (Tavor)
3.	Deamino Arginine Vasopressin (Desmopressin)
4.	Cholinergic Antagonists (Anticholinergics)
5.	Imipramine (Janimine)
6.	propiverine
7.	tyramine-deoxysorbitol
8.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
9.	darifenacin
10.	Flavoxate (Urispas)
118 Drugs and Important Bio-Agents and 184 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Biofeedback (Psychology) (Biofeedback)
3.	Prostatectomy (Retropubic Prostatectomy)
4.	Home Nursing (Nursing, Home)
5.	Kampo Medicine (Kampo)
12 Therapies and Procedures and 17 more articles analyzed in the Research Interface, order at left...